Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(59)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NW\FZY1qS3m2b4TvfIlkKEG|c3H5 NYHSTZNrOTBibl2= MkPwO|IhcA>? MkfLSG1UVw>? NV\uW3pMWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MoT3NlQ6ODB6N{O=
HT-29 MlWyR5l1d3SxeHnjJGF{e2G7 M1fmNVExKG6P NHnzUok4OiCq NYjNeJBITE2VTx?= NFKxZmNRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= MVqyOFkxODh5Mx?=
HT-29 MXrDfZRwfG:6aXOgRZN{[Xl? NHzWcZoyOCCwTR?= NELSSFM4OiCq NHTyW2pFVVOR NHnsZZlRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MnLjNlQ6ODB6N{O=
PC3 NGPkVmdMcW6jc3WgRZN{[Xl? Ml3DNVAxKG6P NVO4NFRiOSCq MWTEUXNQ MYjQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= MmjYNlE6Pzh4OEO=
PC3 M1\6UGtqdmG|ZTDBd5NigQ>? NGG1UnUyODBibl2= MVSxJIg> MlTrSG1UVw>? M3rXPGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MWWyNVk4QDZ6Mx?=
PC3 NGjJTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFroR|AyNjVizszN M{ToNFEhcA>? NX[0N2dZTE2VTx?= NH3MPFdKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= MVSyNVk4QDZ6Mx?=
HEK293 M33HWWZ2dmO2aX;uJGF{e2G7 MnPwNVAxKG6P M4rQOlghcA>? NX;CZWZVTE2VTx?= MYPJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? MX2yNVU{QTNyMR?=
BT-20 NVnNc40xU2mwYYPlJGF{e2G7 MXSyNEDPxE1? MVnEUXNQ MYfEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? Mn:1NlE{PTN3NUG=
U937 MVXBcpRq[mGldHXybYFtKEG|c3H5 MojGOVAh|ryP MmrEOFghcA>? M3LsS2ROW09? MkP3TY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NFvEfJMzOTF2MkGwOi=>
U937 M{jEeWFvfGmkYXP0[ZJq[WxiQYPzZZk> NGXneJE2OCEQvF2= M2n2TlQ5KGh? MXTEUXNQ MUjEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ MX:yNVE1OjFyNh?=
U937 NV\BUm15SW62aXLhZ5RmemmjbDDBd5NigQ>? MVu1NEDPxE1? M1rHT|Q5KGh? MnHDSG1UVw>? MWXEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MUGyNVE1OjFyNh?=
MCF-7 M3n2R2F2fG:yaHHnfUBCe3OjeR?= NH63flA{OCCwTR?= NYW2SVZWPCCq MVzEUXNQ M1n1NWlv\HWlZYOgZZV1d3CqYXf5 MlTONlAxOjhzM{S=
U87MG MkX4T4lv[XOnIFHzd4F6 M{jNflEh|ryP M3HJO|YhcA>? MnjBSG1UVw>? NX3E[GxiWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= MWqxPVg1QDRyNB?=
U87MG M4SxVmtqdmG|ZTDBd5NigQ>? M{HIZ|Eh|ryP MYe2JIg> MmPzSG1UVw>? Ml\qVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= MWOxPVg1QDRyNB?=
U87MG MX7LbY5ie2ViQYPzZZk> MVWxJO69VQ>? NF3NW4Q3KGh? MV7EUXNQ M2\td2Rw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NUf0TmRDOTl6NEi0NFQ>
U87MG MmTNT4lv[XOnIFHzd4F6 M{DpXFEh|ryP M3H0elYhcA>? MUDEUXNQ MYTEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> M{\5XFE6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb NUnZUIJ1SXW2b4DoZYd6KEG|c3H5 NH;0TXkxNjJizszN NFT5XlIzPCCq MVrEUXNQ MXXJcoR2[2W|IHH1eI9xcGGpeR?= NH3qW3gyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 MXLBeZRweGijZ4mgRZN{[Xl? M3jyS|AvOiEQvF2= M1zSXlI1KGh? M4PWVmROW09? NH\nSldKdmS3Y3XzJIF2fG:yaHHnfS=> MYmxPFM6OTl2OR?=
H4 NVXpT3FETnWwY4Tpc44hSXO|YYm= M{fUbFAvOiEQvF2= MnrlNlQhcA>? MXjEUXNQ Ml3MTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> NILufFIyQDB{NEW4OC=>
HeLa MYnGeY5kfGmxbjDBd5NigQ>? Mnm3NVAxKG6P NWTYTlU6OzZiaB?= MWXEUXNQ MUXJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u NWnXWoxkOTd3NkOzPFU>
HeLa NGPOT2dHfW6ldHnvckBCe3OjeR?= NH7hb5oyODBibl2= M{Lwe|M3KGh? NF6w[5BFVVOR MlrLTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M3rFRlE4PTZ|M{i1
HeLa MXHGeY5kfGmxbjDBd5NigQ>? NU\Le3UyOTByIH7N MkDPN|YhcA>? NELlNXRFVVOR MlXoTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NEj6fJQyPzV4M{O4OS=>
SYF MYfGeY5kfGmxbjDBd5NigQ>? MlTxNVAxKG6P M4XPclI1KGh? NFHZ[YdFVVOR NEn0fmxKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> MUCxO|U3OzN6NR?=
SYF NFfJXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn6NVAxKG6P NES0TlIzPCCq NFi5V5RFVVOR MYrJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| M3zlVlE4PTZ|M{i1
HEK293T M{TzS2FvfGm4aYLhcEBCe3OjeR?= NXvwOFlLOSCwTR?= NHLrbms1KGR? NFfhcGlFVVOR NELsfI5KdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> NXH6TVFpOTd2OEW1NFE>
HEK293T NFS5bphCdnSrdnnyZYwhSXO|YYm= NXLkPYc1OSCwTR?= NUO0XmQzPCCm NIPoNHBFVVOR MWPJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NITT[FIyPzR6NUWwNS=>
PBMC NX32NIdxTnWwY4Tpc44hSXO|YYm= MkHwNUBvVQ>? NGDOd|YyPCCm M1PDSmROW09? MnnjVoVlfWOnczDDR3I2KGSnboPpeJk> M2TjRVE4PDh3NUCx
PBMC MWjGeY5kfGmxbjDBd5NigQ>? MkfWNUBvVQ>? NIe2bpkyPCCm M1\nSGROW09? MlnXSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> MonINVc1QDV3MEG=
HEK293 cells M3rDcWtqdmG|ZTDBd5NigQ>? M2m4NVUxKG6P NXLMe5J4PDVibXnu MWLEUXNQ NFztTHNKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P M4e5SVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MWfGeY5kfGmxbjDBd5NigQ>? NF\x[mYyODBibl2= MYO0JIg> M4\RR2ROW09? NUTte|RGUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NXn0UmxLOTdzMkiyOlI>
Human mixed lymphocyte NYnRZ2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[1JI5O MYTEUXNQ M37ybGlEPTB;MT62JI5ONg>? M1LybFE3OTh3OE[1
Lewis rat lymph node cells NUe1dHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETLbpk2KM7:TR?= NX\X[pZ6TE2VTx?= NXPkc3hEUUN3ME2yMlYh|ryP MmTQNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice M1nm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULSO2JqOTBibl2= MnXpO|IhcA>? MlTOSG1UVw>? M1jlZWlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= Mk\pNVAxOjF7NEi=
MRK-nu-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXPU4dKSzVyPUCuPFQ2KHCP M{PrenNCVkeHUh?=
OCUB-M MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzrcXpVUUN3ME21MlI1KHCP NWj2NphGW0GQR1XS
SF539 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D4fGlEPTB;MUGuOkBxVQ>? MlW3V2FPT0WU
ES4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJzLkWgdG0> MV;TRW5ITVJ?
RL95-2 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFyNzDwUS=> NUfsVHpEW0GQR1XS
LC-2-ad Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\lTWM2OD12MkOgdG0> MVzTRW5ITVJ?
Daudi NVrob5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3STWM2OD12M{SgdG0> MmjTV2FPT0WU
NTERA-S-cl-D1 NX20RZVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfNTWM2OD12NEOgdG0> NGrXe4xUSU6JRWK=
OS-RC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDiOohFUUN3ME22OVIheE1? M{TJ[3NCVkeHUh?=
VA-ES-BJ NWrQTlVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu5VpZKSzVyPUeyN{BxVQ>? M3TUenNCVkeHUh?=
GR-ST NEXuVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XBWGlEPTB;OES2JJBO NFfxT25USU6JRWK=
SW872 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTh2NjDwUS=> MVvTRW5ITVJ?
NOS-1 NXHlUYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTh5MTDwUS=> NVXQNGpJW0GQR1XS
MC116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HZdmlEPTB;OUi1JJBO NUnOU21rW0GQR1XS
NCI-H1355 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPkXG5KSzVyPUGuNFEhdk1? Ml33V2FPT0WU
RPMI-8226 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjWeWRKSzVyPUGuNVkhdk1? NGfrXpNUSU6JRWK=
TE-15 M3TGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnCTWM2OD1zLkO2JI5O MX3TRW5ITVJ?
Ramos-2G6-4C10 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPTTWM2OD1zLkS2JI5O MlTmV2FPT0WU
KU812 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknqTWM2OD1{LkCxJI5O MVTTRW5ITVJ?
EW-1 NYHOeo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TVSWlEPTB;Mj6xO{BvVQ>? NYD2dFlMW0GQR1XS
KS-1 NHjON5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S5WWlEPTB;Mj60OUBvVQ>? NWr0V3RpW0GQR1XS
SK-LMS-1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLYTWM2OD1{LkS5JI5O MlnhV2FPT0WU
TGBC1TKB NILMZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPrT4FtUUN3ME2yMlY6KG6P MYnTRW5ITVJ?
TE-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHLOYFKUUN3ME2yMlc4KG6P MkL3V2FPT0WU
ETK-1 NV[5c5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkToTWM2OD1{LkiyJI5O MlS3V2FPT0WU
BE-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwOUmgcm0> M1TFPXNCVkeHUh?=
A3-KAW NGXJR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vIRmlEPTB;Mj65PUBvVQ>? MWDTRW5ITVJ?
TE-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PKSWlEPTB;Mz6zJI5O NW\6V5F6W0GQR1XS
DOHH-2 NEfyNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrOVIhKSzVyPUOuN|Uhdk1? MUPTRW5ITVJ?
ES6 M1n2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GzZ2lEPTB;Mz60N{BvVQ>? NX3F[XJwW0GQR1XS
OPM-2 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwMUWgcm0> MV;TRW5ITVJ?
SH-4 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL2XmY3UUN3ME20MlM1KG6P Mly4V2FPT0WU
NB13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjjV5RKSzVyPUSuN|Yhdk1? NGfUTYFUSU6JRWK=
HUTU-80 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRwNEKgcm0> MnLKV2FPT0WU
CCRF-CEM M322XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjzTWM2OD12Lkm0JI5O MlHtV2FPT0WU
TGBC24TKB M3fTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTVwNUGgcm0> NHnvSVdUSU6JRWK=
697 NFvZ[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLRbWZKSzVyPU[uNlghdk1? NV;rfYJ2W0GQR1XS
J-RT3-T3-5 NUHrNVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDlV5Z[UUN3ME22MlQ3KG6P NXLNfIMxW0GQR1XS
KALS-1 NWLIeVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\mR456UUN3ME22MlU3KG6P M4jp[nNCVkeHUh?=
no-10 M3nQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jvdGlEPTB;Nz6yPUBvVQ>? Mn\iV2FPT0WU
SK-NEP-1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwN{mgcm0> NXPMeVRyW0GQR1XS
L-540 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDWTWM2OD1zMD60NkBvVQ>? NHrYUVlUSU6JRWK=
JiyoyeP-2003 M4[3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFyLkm0JI5O NU\XR2s2W0GQR1XS
HH NFvVW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFzLkO5JI5O MX\TRW5ITVJ?
SR Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrTS2VSUUN3ME2xNU41PSCwTR?= MVnTRW5ITVJ?
QIMR-WIL NWjXU4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVztV|dLUUN3ME2xNU45PSCwTR?= MUPTRW5ITVJ?
A4-Fuk MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjjTXBnUUN3ME2xN{4yOiCwTR?= NIG0WlhUSU6JRWK=
CESS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7uTWM2OD1zMz6xN{BvVQ>? Ml[yV2FPT0WU
KE-37 NWPzXmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LKR2lEPTB;MU[uNFchdk1? M2rLb3NCVkeHUh?=
SK-UT-1 NFfHVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TLS2lEPTB;MU[uPFEhdk1? NIG2b5JUSU6JRWK=
SIG-M5 NWHUV2FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvrTWM2OD1zNz6yOUBvVQ>? NI\NSVFUSU6JRWK=
HT NUTYOYl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nhfWlEPTB;MUeuOkBvVQ>? M4Hke3NCVkeHUh?=
DEL MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD1VXloUUN3ME2xO{46QSCwTR?= MVvTRW5ITVJ?
SK-PN-DW MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJyLkKzJI5O M2fL[XNCVkeHUh?=
RPMI-8402 M4PxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvwTWM2OD1{MT63O{BvVQ>? NXzZWGEyW0GQR1XS
RPMI-6666 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK1[GNRUUN3ME2yOE41OiCwTR?= NULEZXFXW0GQR1XS
NCI-H720 NULNWnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ3LkSxJI5O M{XBenNCVkeHUh?=
EW-16 NIjDOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILkXGJKSzVyPUK2Mlg4KG6P NH7sVJhUSU6JRWK=
BL-70 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ObYpQUUN3ME2yPE4{QCCwTR?= MnLCV2FPT0WU
SF126 M4r1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnzTWM2OD1|MD6zPEBvVQ>? MU\TRW5ITVJ?
BC-1 NHzjRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNzLkK2JI5O NXTXZodwW0GQR1XS
MHH-PREB-1 NXPyd4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7tSFNoUUN3ME2zNk41PCCwTR?= MV;TRW5ITVJ?
A101D NIC4U|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP5W|NMUUN3ME2zNk43OiCwTR?= MnjLV2FPT0WU
NMC-G1 NX;HWmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN|Lk[3JI5O NYnpNYR[W0GQR1XS
LB1047-RCC NGfpXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jxcWlEPTB;M{SuOlkhdk1? Mmi0V2FPT0WU
EM-2 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\iR5BKSzVyPUO4MlU{KG6P NHnOdlJUSU6JRWK=
COLO-684 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPpWIZkUUN3ME2zPU45KG6P MX;TRW5ITVJ?
Becker M{\ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXTFRjUUN3ME20NU4xPSCwTR?= NEWxfo1USU6JRWK=
BL-41 NGnMUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TmNGlEPTB;NEOuOlYhdk1? NEnYfHlUSU6JRWK=
MDA-MB-134-VI NWj3cWZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn6R5B{UUN3ME20OE4xOiCwTR?= MkfqV2FPT0WU
L-363 NHfqRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi5UYNFUUN3ME20OE44OyCwTR?= MkDrV2FPT0WU
ECC4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3LNZRKSzVyPUS0Mlc5KG6P MXjTRW5ITVJ?
A388 NFLBW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ibWlEPTB;NESuPFIhdk1? Ml[5V2FPT0WU
HEL NXXIWZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR7Lke5JI5O MYrTRW5ITVJ?
RKO Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n1SWlEPTB;NUCuNlkhdk1? Ml6xV2FPT0WU
KINGS-1 NHW1OXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qyemlEPTB;NUGuOVUhdk1? MoexV2FPT0WU
EB-3 NXe1cmNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTV{Lk[3JI5O M3K4XnNCVkeHUh?=
ARH-77 M3PIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTV{Lkigcm0> NFvLfppUSU6JRWK=
GCIY M3[wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC0TWM2OD13Mz60OkBvVQ>? M2fweXNCVkeHUh?=
NCI-H1304 NUTuZ3pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X4VmlEPTB;NUeuNlIhdk1? M32xOXNCVkeHUh?=
KARPAS-299 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6yTWM2OD14MT64NkBvVQ>? MmnPV2FPT0WU
IA-LM MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PwR2lEPTB;NkiuNVMhdk1? M{TrVXNCVkeHUh?=
GI-1 NVGzV5l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjYW|NbUUN3ME23NE4{QSCwTR?= Mm[wV2FPT0WU
TE-11 NX3XeoNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXiTWM2OD15Nz6xO{BvVQ>? MoXUV2FPT0WU
LS-411N MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTd5LkW3JI5O M4C4W3NCVkeHUh?=
no-11 M4PwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTJNIRxUUN3ME24N{4zPCCwTR?= MnrLV2FPT0WU
MV-4-11 NF\DeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvSTWM2OD16Mz63N{BvVQ>? NWPl[pJQW0GQR1XS
BV-173 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPETWM2OD16Mz65O{BvVQ>? NEnKSplUSU6JRWK=
CMK M1rTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fl[WlEPTB;OESuNVYhdk1? M3vxTnNCVkeHUh?=
LC4-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTh4LkeyJI5O MWjTRW5ITVJ?
COR-L279 NVnwSIFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDCXHdKSzVyPUi3MlI2KG6P MWjTRW5ITVJ?
NCI-H209 M2[2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTh5LkSxJI5O M1XjW3NCVkeHUh?=
Raji NYeyT3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPr[HlXUUN3ME24PU44OiCwTR?= NXzKblNyW0GQR1XS
LB996-RCC NFTJTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTl|LkSzJI5O NH33W3VUSU6JRWK=
NCI-H526 M{nwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPXblNKSzVyPUmzMlU6KG6P NYXw[JYxW0GQR1XS
KGN MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXTTWM2OD17Nj6yPUBvVQ>? NVrKWoxUW0GQR1XS
MOLT-4 M2ToVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXaepFKSzVyPUm2Mlc6KG6P MmL0V2FPT0WU
PF-382 NWrNeY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPXcVZKSzVyPUm2Mlc6KG6P MVLTRW5ITVJ?
BC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPnb2hKSzVyPUm5MlE5KG6P NWH0OINUW0GQR1XS
KARPAS-422 NH33cWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS1VmFKSzVyPUGwNk4xQSCwTR?= MoX3V2FPT0WU
SBC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETCNnVKSzVyPUGwO{44PSCwTR?= MkjBV2FPT0WU
LC-1F MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyOD6wOUBvVQ>? NUXOVZlyW0GQR1XS
GB-1 NXzYRmp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrmTWM2OD1zMEmuNFIhdk1? MlLBV2FPT0WU
SNB75 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HGUWlEPTB;MUG5MlY6KG6P M1fYU3NCVkeHUh?=
BB65-RCC NVvHWY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX6TWM2OD1zMUmuPVMhdk1? NXn3N|lnW0GQR1XS
NCI-N87 NX:xTY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT3b5RKSzVyPUGyNU46QCCwTR?= MY\TRW5ITVJ?
IST-MEL1 NEnqVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L3T2lEPTB;MUKyMlM5KG6P NX7LcGNrW0GQR1XS
HOP-62 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfROJFKSzVyPUGyOk45QSCwTR?= M{HKR3NCVkeHUh?=
ACN M2PhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF2Nj63OUBvVQ>? NYnLdHZiW0GQR1XS
DMS-114 NVXVdYdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK0TWM2OD1zNUCuOlchdk1? M4W5b3NCVkeHUh?=
MLMA MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TXemlEPTB;MUW5Mlg5KG6P MU\TRW5ITVJ?
HT-144 NHHhOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYric4lyUUN3ME2xOlUvPDNibl2= NIq5cmVUSU6JRWK=
C2BBe1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jPOWlEPTB;MU[3Mlc3KG6P MV3TRW5ITVJ?
L-428 M3Tm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W2OWlEPTB;MUe3Mlchdk1? NIe0eGdUSU6JRWK=
DU-4475 NF;3SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4fmlEPTB;MUi3MlY5KG6P NHzyXmxUSU6JRWK=
CP67-MEL M3nqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXySHlKSzVyPUG5PU4{QCCwTR?= M3y1VnNCVkeHUh?=
MEG-01 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzYeXRKSzVyPUKwNU46PiCwTR?= NILaSIhUSU6JRWK=
IST-SL2 NWPON|ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLqTWM2OD1{MEiuOlMhdk1? M1nSVXNCVkeHUh?=
ES8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjre282UUN3ME2yNlUvQTRibl2= Mly5V2FPT0WU
COLO-800 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHae3JQUUN3ME2yN|UvOjhibl2= NVrDPGFZW0GQR1XS
MFH-ino M1nvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zrNGlEPTB;MkO1Mlg1KG6P NHnHd4lUSU6JRWK=
OVCAR-4 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ|Nz6yOEBvVQ>? Mn;uV2FPT0WU
PSN1 NXe5TI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT4O|JKSzVyPUK0Nk44OSCwTR?= NHrBdnZUSU6JRWK=
EW-12 NIfufGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm5eY5UUUN3ME2yOFMvOSCwTR?= Ml\IV2FPT0WU
HCC1599 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH5V|BKSzVyPUK2NU41PyCwTR?= MnrZV2FPT0WU
SJSA-1 NFuyNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;n[2lEPTB;MkexMlQ3KG6P NVH1cJF{W0GQR1XS
ST486 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnKPIRwUUN3ME2yPVYvOTRibl2= MVzTRW5ITVJ?
NOMO-1 NFjvelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TN[2lEPTB;M{CwMlIyKG6P MVHTRW5ITVJ?
MN-60 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\a[INKSzVyPUOwOU4{OiCwTR?= MVnTRW5ITVJ?
HCC1187 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojGTWM2OD1|MEeuNlUhdk1? NUnsTIh7W0GQR1XS
SW982 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTNzND63OUBvVQ>? M3PPeHNCVkeHUh?=
LB647-SCLC M1PhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN{OD63NUBvVQ>? NF3NU2dUSU6JRWK=
HC-1 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1THNGlEPTB;M{O1MlUhdk1? NIrrfVBUSU6JRWK=
EHEB NHvzZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TPcmlEPTB;M{O3MlUzKG6P NH7HOohUSU6JRWK=
TUR MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiwVYZKSzVyPUO2N{46PSCwTR?= MYfTRW5ITVJ?
LU-139 NHLRdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD1|N{iuNFIhdk1? MWrTRW5ITVJ?
NB1 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTN6ND60OUBvVQ>? NWDveIhNW0GQR1XS
BB30-HNC NHzzb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN6OD6zNkBvVQ>? MVjTRW5ITVJ?
HAL-01 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXflOpJKUUN3ME2zPFkvOjZibl2= MnHvV2FPT0WU
K5 NX;UcldxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rSWmlEPTB;NEGxMlM4KG6P M17pOnNCVkeHUh?=
MZ2-MEL MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fWfmlEPTB;NEGzMlY1KG6P MVXTRW5ITVJ?
RXF393 M17icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfNTWM2OD12MU[uOFUhdk1? NGrReWVUSU6JRWK=
NCI-H1648 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzON4pKSzVyPUSxO{42OyCwTR?= NV\XWFhEW0GQR1XS
TE-12 M1PKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\iNmlEPTB;NEO0MlI3KG6P NFHqeZVUSU6JRWK=
EoL-1- MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR|Nz65PEBvVQ>? MYHTRW5ITVJ?
JAR MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf6d|BKSzVyPUSzPE43OiCwTR?= NVjUcXYyW0GQR1XS
DSH1 NGjYboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXHXItKSzVyPUS1PE46OSCwTR?= NUHnfYVyW0GQR1XS
NCI-H187 NUHXNHliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rhT2lEPTB;NE[yMlgyKG6P MWrTRW5ITVJ?
HCE-4 NVnXT4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR5Nz62OkBvVQ>? NHvBe3ZUSU6JRWK=
8-MG-BA M4fPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1PXhoUUN3ME21PFEvPTJibl2= M1;Cb3NCVkeHUh?=
KLE Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjXZYhKSzVyPUW4OU4zKG6P MljNV2FPT0WU
KNS-42 NWC5bYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorpTWM2OD13OE[uPFEhdk1? NVmyeZdVW0GQR1XS
MSTO-211H MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUcm4zUUN3ME22NFkvPzRibl2= Ml[xV2FPT0WU
GDM-1 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zmdmlEPTB;NkG0MlA6KG6P MUPTRW5ITVJ?
TE-1 NYr5SFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[zUnJRUUN3ME22OFYvOTJibl2= NGSzdlFUSU6JRWK=
BT-474 NXntWYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q1XmlEPTB;NkS3MlA3KG6P MXnTRW5ITVJ?
KARPAS-45 NX7mOZN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fpcGlEPTB;NkS3MlYhdk1? M{LXNnNCVkeHUh?=
MOLT-16 NFTVb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTZ2Nz65N{BvVQ>? M4DX[XNCVkeHUh?=
KURAMOCHI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37FUWlEPTB;NkW3MlUyKG6P NFe2ToJUSU6JRWK=
K-562 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXIc5oyUUN3ME22OlkvPTFibl2= MlHYV2FPT0WU
EKVX M3rsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZ5Mj63NUBvVQ>? NXyyR2FtW0GQR1XS
GAK NHuwNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOxTWM2OD14N{WuN{BvVQ>? NITNSnhUSU6JRWK=
NCI-SNU-5 M1TuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTDOZBuUUN3ME22PVAvODFibl2= NX\uV5VtW0GQR1XS
NCI-H2126 NX34PFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP4S2RvUUN3ME23NlYvQDdibl2= M3;NenNCVkeHUh?=
CTV-1 M{fLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULOR4VCUUN3ME23OFQvQSCwTR?= M3vKdXNCVkeHUh?=
SW962 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjmSINKSzVyPUe0PE41PCCwTR?= NUPBdXhnW0GQR1XS
MONO-MAC-6 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne4TWM2OD15NU[uPVMhdk1? M2D1fHNCVkeHUh?=
NCI-H748 NVPLfZg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTd3OD65PUBvVQ>? M37FPHNCVkeHUh?=
NCI-H524 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHezWGxKSzVyPUe4NE44OyCwTR?= M3jWT3NCVkeHUh?=
LS-123 M1HGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jUUmlEPTB;N{m1MlY6KG6P NFPlUpRUSU6JRWK=
NB7 M4DRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj1TWM2OD16MUSuNVQhdk1? NHL3fI5USU6JRWK=
LS-1034 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTadphKSzVyPUiyPE46QCCwTR?= MXHTRW5ITVJ?
TE-5 M{W5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PQXGlEPTB;OEizMlU3KG6P NFjveWRUSU6JRWK=
A704 NGC2SnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTh7OT6xOUBvVQ>? NH\X[|VUSU6JRWK=
TK10 NWDoeo1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P6OmlEPTB;OUG2MlA{KG6P NWrEOI56W0GQR1XS
NCI-H345 NV;X[YZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTl2Mz6yNkBvVQ>? NVLEdHh7W0GQR1XS
CGTH-W-1 M4K5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\EUlNZUUN3ME25OFgvOTNibl2= M3rzVXNCVkeHUh?=
NCI-H510A M{fVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHqTXNGUUN3ME25PFUvOTJibl2= MUHTRW5ITVJ?
NCI-H1963 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwMEOyPVIh|ryP NGT0WldUSU6JRWK=
SCC-3 NEHRUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH6TWM2OD1zLkCzOFE1KM7:TR?= NFjaTmpUSU6JRWK=
EW-11 NVv4cZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXqTWM2OD1zLkC4O|Q{KM7:TR?= NIqwTJRUSU6JRWK=
CPC-N NXW4WoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXSUWpMUUN3ME2xMlA5QCEQvF2= MmK0V2FPT0WU
NCI-H1417 NFS2ZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmwTWM2OD1zLkGyNlYh|ryP NHv2[Y9USU6JRWK=
DG-75 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fzVmlEPTB;MT6xOlI5PSEQvF2= NFzmR45USU6JRWK=
HD-MY-Z MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMU[0NVYh|ryP NWjjOYpVW0GQR1XS
ATN-1 NXXRRnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3VOYhKSzVyPUGuNlYzODlizszN M4\s[HNCVkeHUh?=
KM-H2 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ZS2hjUUN3ME2xMlI3PDB6IN88US=> NF3Qe2JUSU6JRWK=
NCI-H2081 M3rTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1zLkK2OlM4KM7:TR?= M1PvWHNCVkeHUh?=
HL-60 NIC5XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXpU5VKSzVyPUGuNlY6PTlizszN MnfpV2FPT0WU
DB MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rybmlEPTB;MT6yO|I1OiEQvF2= MnvKV2FPT0WU
NCI-H1522 NGX2[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrSeZhKSzVyPUGuNlg5QDdizszN M3fTU3NCVkeHUh?=
AM-38 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwM{C3NkDPxE1? MWHTRW5ITVJ?
NCI-H446 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;VfJlKSzVyPUGuN|IyOjFizszN MYrTRW5ITVJ?
SU-DHL-1 NUjnS5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGxWodKSzVyPUGuN|I5ODFizszN MmPCV2FPT0WU
NH-12 NUizWpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjwTWM2OD1zLkO2N|c1KM7:TR?= M2HkdXNCVkeHUh?=
DMS-79 NFOyWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGySoozUUN3ME2xMlM3QDZ4IN88US=> MlvBV2FPT0WU
NCI-H716 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwM{i5PFYh|ryP M{LYR3NCVkeHUh?=
ML-2 M{PU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHVTWM2OD1zLkSxOVI6KM7:TR?= MVvTRW5ITVJ?
NB10 NGT2XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\he41nUUN3ME2xMlQ3PjN{IN88US=> MoGxV2FPT0WU
ONS-76 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwNUO1Olkh|ryP NYfXWnl6W0GQR1XS
LOUCY MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GwXWlEPTB;MT61OFY2PyEQvF2= MXPTRW5ITVJ?
SCLC-21H MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm1bGg{UUN3ME2xMlU5PTh{IN88US=> NVLDPGhRW0GQR1XS
TGW Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX2TWM2OD1zLk[zPVc2KM7:TR?= NFTuVmJUSU6JRWK=
LXF-289 NGfib4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHKTWM2OD1zLkezNlY5KM7:TR?= NFjyRoNUSU6JRWK=
BB49-HNC NFX4bWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwN{O1PFYh|ryP M1jzcnNCVkeHUh?=
NCI-H747 NYTKe5QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrwNYdVUUN3ME2xMlc2OzR4IN88US=> NXW0bJltW0GQR1XS
LU-165 NHSydINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrdVJPUUN3ME2xMlg1QTh4IN88US=> MY\TRW5ITVJ?
OMC-1 NU\hW2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1RZlTUUN3ME2xMlk2ODZ4IN88US=> NVfrfYpIW0GQR1XS
RCC10RGB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13sZ2lEPTB;MT65OVgyPyEQvF2= M2KxVHNCVkeHUh?=
SW684 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7CTWM2OD1zLkm2NFk6KM7:TR?= M4XhPHNCVkeHUh?=
TE-8 NEjobJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn35TWM2OD1{LkC1OVU6KM7:TR?= M1\RbnNCVkeHUh?=
SK-N-DZ MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDlOVhsUUN3ME2yMlE{Ojd2IN88US=> NGnCeVJUSU6JRWK=
EVSA-T M{LFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfaXlFKSzVyPUKuNVc{OTVizszN NYDVeXN6W0GQR1XS
KASUMI-1 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwMUi4NVUh|ryP NGS2XYVUSU6JRWK=
NKM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwMkW0O|Ih|ryP MUDTRW5ITVJ?
CAL-148 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDBTWM2OD1{LkOzOlE1KM7:TR?= NEPSXGpUSU6JRWK=
NCI-H64 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTES|J6UUN3ME2yMlM1OjN{IN88US=> Mo[4V2FPT0WU
KNS-81-FD NWD2dGFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HyOGlEPTB;Mj6zOlYzKM7:TR?= MlywV2FPT0WU
KM12 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjyTYlKSzVyPUKuOFA5OzlizszN M1nKRnNCVkeHUh?=
SW954 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DhS2lEPTB;Mj60O|c4QSEQvF2= MULTRW5ITVJ?
NCI-H1395 M1vqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PiWGlEPTB;Mj61NlY1PSEQvF2= MWrTRW5ITVJ?
DJM-1 M1nTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmxTWM2OD1{Lk[wOlMh|ryP NIXXUXpUSU6JRWK=
COLO-668 NEDsPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwOEK2PVUh|ryP NYjBb|JvW0GQR1XS
NCI-H1436 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\TTWM2OD1{Lki1OlE2KM7:TR?= MWrTRW5ITVJ?
LB2241-RCC MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHZNGF3UUN3ME2yMlg3QDN7IN88US=> MlXNV2FPT0WU
GT3TKB MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\ndolKSzVyPUKuPFkxPTVizszN NWXke|c6W0GQR1XS
COLO-824 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJwOEm3Olgh|ryP NFm3VmtUSU6JRWK=
ES1 NX;FNnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0UmdKSzVyPUKuPFk5PzlizszN M3H2RXNCVkeHUh?=
LB771-HNC NI\Z[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnWTWM2OD1{LkmwPVQ3KM7:TR?= NGXPZ3pUSU6JRWK=
GI-ME-N NH\STmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2SGlEPTB;Mz6wNFkxPCEQvF2= MnXQV2FPT0WU
NALM-6 NIDDeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1e2VKSzVyPUOuNFA6OzNizszN Ml;HV2FPT0WU
LU-134-A NV7JNHlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfZSHNKSzVyPUOuNFU1OjVizszN NUX3NWdXW0GQR1XS
DMS-153 NFPIZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i3c2lEPTB;Mz6wOVgzPCEQvF2= M{nlcHNCVkeHUh?=
MZ1-PC NUj3doY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;wXnVKSzVyPUOuNFkxPzhizszN MV;TRW5ITVJ?
NCI-H1155 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\TN2lEPTB;Mz6xNVYyKM7:TR?= NFLMUmxUSU6JRWK=
CAS-1 M4DYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNwMUO3NFch|ryP M3y3XnNCVkeHUh?=
D-502MG NF30fHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS1TWM2OD1|LkG0N|kh|ryP NIPyfZRUSU6JRWK=
NCI-H2141 M37jVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjXRYRKSzVyPUOuNVc1PTJizszN MWrTRW5ITVJ?
NB6 NHHFfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLMV3BtUUN3ME2zMlE5OjV7IN88US=> NFPBNGlUSU6JRWK=
NCCIT NUHOZ5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f3bGlEPTB;Mz6yNVgxQSEQvF2= MmLDV2FPT0WU
NB69 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;6XGlEPTB;Mz6zNVg6OSEQvF2= NEGxcFZUSU6JRWK=
JVM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5emhKSzVyPUOuN|Y1OzNizszN NYnX[YlQW0GQR1XS
K052 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS3TWM2OD1|LkO3PVY5KM7:TR?= NELlSo1USU6JRWK=
HCC2157 NGXMPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[5NoRKSzVyPUOuOVMzOjhizszN MnP3V2FPT0WU
KMOE-2 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3tWHlKSzVyPUOuOVQzPDJizszN NX;1eVRQW0GQR1XS
SF268 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HxVmlEPTB;Mz63NVU2PCEQvF2= Mki1V2FPT0WU
CHP-126 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpNWlEPTB;Mz63OlQ2QCEQvF2= M2LJeHNCVkeHUh?=
CP66-MEL M33yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2[phKSzVyPUOuO|kxQTRizszN NIDPfFZUSU6JRWK=
NCI-H69 NEC4fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPDUWtKSzVyPUSuNFE6OzZizszN MkPpV2FPT0WU
A253 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP5Z5RKSzVyPUSuNFIyODFizszN MUDTRW5ITVJ?
NB14 NUG0TJRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\EPZNKSzVyPUSuNVA1PzlizszN NEPi[5VUSU6JRWK=
NCI-H1694 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\kb4VMUUN3ME20MlE{OTF{IN88US=> NUGwcZVqW0GQR1XS
NCI-H2196 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzkW255UUN3ME20MlE4OTZ7IN88US=> NYG3[3hbW0GQR1XS
TE-9 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\FR4hKSzVyPUSuNVc2QDJizszN NE\DOWlUSU6JRWK=
D-283MED NH;EOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXxTWM2OD12LkG4PFQh|ryP M3XsTXNCVkeHUh?=
OCI-AML2 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwMUm0PFkh|ryP M4TjXnNCVkeHUh?=
D-263MG NHfvR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwMkK5OlEh|ryP M1flUnNCVkeHUh?=
MPP-89 M{LyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfTTWM2OD12LkK3N|A1KM7:TR?= MWPTRW5ITVJ?
LAMA-84 M1jvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7H[pQ6UUN3ME20MlMxPDJzIN88US=> M2fPe3NCVkeHUh?=
LB373-MEL-D NUe3dHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon6TWM2OD12LkO2O|g6KM7:TR?= Mn75V2FPT0WU
UACC-257 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzlOY5TUUN3ME20MlM6PTN2IN88US=> NGm5U5dUSU6JRWK=
MC-CAR MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Ie2tKSzVyPUSuOFM6QSEQvF2= MnzwV2FPT0WU
COLO-320-HSR M37lemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRwNES0Nlch|ryP MUDTRW5ITVJ?
P30-OHK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTMcYttUUN3ME20MlY3PThzIN88US=> NYW3WGE{W0GQR1XS
UACC-812 NUjGb5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwNkmxOlEh|ryP M4\XdHNCVkeHUh?=
CTB-1 NVj0c|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXoTWM2OD12LkexOVU2KM7:TR?= MYrTRW5ITVJ?
ALL-PO Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC2TWM2OD12Lki0NFc4KM7:TR?= NVXobHFOW0GQR1XS
SK-MEL-2 M3L5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TpVWlEPTB;ND64Olk2PSEQvF2= MVXTRW5ITVJ?
TC-YIK NX[0cHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP1TWM2OD12Lkm3PVQzKM7:TR?= MWDTRW5ITVJ?
NCI-H1882 NUDmW5JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3Fco9KSzVyPUWuNFIxODFizszN NV;MfnpxW0GQR1XS
MHH-CALL-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTVwMEWwOFIh|ryP MVfTRW5ITVJ?
U-87-MG NH7Ue2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjHTWM2OD13LkC5OFY3KM7:TR?= MoHrV2FPT0WU
NCI-H1092 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mydGlEPTB;NT6yOlU2PSEQvF2= NH\Xe3pUSU6JRWK=
TE-441-T MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH4TWM2OD13LkK3PFIh|ryP MYHTRW5ITVJ?
SK-MEL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L0PWlEPTB;NT6yPVA1PCEQvF2= NFvKZplUSU6JRWK=
EW-22 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LiUmlEPTB;NT6yPVQ3PiEQvF2= M2O1OXNCVkeHUh?=
MZ7-mel MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KWY8xUUN3ME21MlQxPjlzIN88US=> NEDEbG9USU6JRWK=
LP-1 NGLYeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jBOGlEPTB;NT60NVI6OSEQvF2= NXTMUoI3W0GQR1XS
NCI-SNU-16 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:2TWM2OD13Lk[0NFc1KM7:TR?= MonUV2FPT0WU
LU-65 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHTeXBKSzVyPUWuO|Y{PzNizszN NF;uc4FUSU6JRWK=
CW-2 NX25c41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwOEW5OVkh|ryP Mn\jV2FPT0WU
WSU-NHL Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTVwOUWxO|Qh|ryP MmHGV2FPT0WU
IST-MES1 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu1TWM2OD13Lkm1OFQ{KM7:TR?= NITEPJhUSU6JRWK=
U-266 NHvje|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fwPWlEPTB;NT65PFIxOiEQvF2= NGnsWItUSU6JRWK=
TALL-1 M1LQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZwMUS2PFgh|ryP NF22eZJUSU6JRWK=
Calu-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37PR2lEPTB;Nj6xOVMyPiEQvF2= M2\VdHNCVkeHUh?=
MMAC-SF NFT3WVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1fJpWUUN3ME22MlE5PTV4IN88US=> MVnTRW5ITVJ?
NCI-H82 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTZwMkC0PFkh|ryP MVvTRW5ITVJ?
RS4-11 NYGwV2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33kWGlEPTB;Nj6yOVg6PyEQvF2= NIToN4tUSU6JRWK=
SNU-C2B NFPlfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiNmlEPTB;Nj60NFk3QSEQvF2= NILZfWRUSU6JRWK=
BOKU M2C5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrSTWM2OD14LkS3OVk4KM7:TR?= M2m5c3NCVkeHUh?=
C8166 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\4OGlEPTB;Nj61OVkyOiEQvF2= M2r0dHNCVkeHUh?=
D-247MG MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRU21KSzVyPUeuNFQ{PDdizszN NHLD[oZUSU6JRWK=
EW-18 M1\xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjmSVhvUUN3ME23MlA4Ojl{IN88US=> NWHSUWgyW0GQR1XS
KG-1 NHS5VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jYOmlEPTB;Nz62Nlc{QCEQvF2= MXfTRW5ITVJ?
REH M{L1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qwSGlEPTB;Nz62PFExQSEQvF2= NFPuUWxUSU6JRWK=
U-698-M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofyTWM2OD15Lki0N|E2KM7:TR?= Mom1V2FPT0WU
KP-N-RT-BM-1 NX7NT2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojwTWM2OD15LkmzNFI6KM7:TR?= NELNPGVUSU6JRWK=
MS-1 NX\kOHJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTdwOU[wOFEh|ryP NWf5fJFxW0GQR1XS
SNU-C1 NYe2WZQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fOXWlEPTB;Nz65PFE6OiEQvF2= MYrTRW5ITVJ?
SK-MM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD16LkK2NFY2KM7:TR?= NFHjd4ZUSU6JRWK=
LAN-6 M4PlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwM{CwNFEh|ryP NUfGdnBLW0GQR1XS
NEC8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jCWmlEPTB;OD6zNFY6OSEQvF2= NUfLSWJTW0GQR1XS
NCI-H1770 NXnKR3N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfZUXlKSzVyPUiuN|gxODJizszN NEO5PIdUSU6JRWK=
D-336MG NYnYcnFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S5ZWlEPTB;OD60NFEyPiEQvF2= NIDR[ohUSU6JRWK=
COLO-829 NVrhT2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\PbJF6UUN3ME24MlQ5QDd7IN88US=> MVPTRW5ITVJ?
LS-513 NV63N3ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXridYlQUUN3ME24MlU6PTl7IN88US=> MlPsV2FPT0WU
YT M2LxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKzTWM2OD16Lk[yOFI4KM7:TR?= NV3jVoFGW0GQR1XS
EW-24 NIj1VJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwN{[1OEDPxE1? MUHTRW5ITVJ?
IST-SL1 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRThwOE[1OFMh|ryP NILHfYFUSU6JRWK=
CA46 NUf2NIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fFbWlEPTB;OD65OVA6QCEQvF2= NVHJ[3A3W0GQR1XS
NCI-H1838 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJTWM2OD16Lkm4OlAzKM7:TR?= M1XNbnNCVkeHUh?=
NCI-H719 MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG1WWh7UUN3ME25MlI2Ojd7IN88US=> NWH6dVU5W0GQR1XS
HCE-T NEO5PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO5TWM2OD17LkOwPFUyKM7:TR?= MVnTRW5ITVJ?
A498 NFvvZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWezS3VlUUN3ME25MlM3OTJ2IN88US=> MYjTRW5ITVJ?
LB831-BLC NYK3PINyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiyTWM2OD17Lke2OVIyKM7:TR?= NIXTT3lUSU6JRWK=
SKM-1 NYi5eGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnoXpNKSzVyPUmuPFU6PjNizszN MVrTRW5ITVJ?
THP-1 M4fMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTlwOU[5NVgh|ryP M1f1ZXNCVkeHUh?=
SHP-77 NIC0VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLkSwO{DPxE1? M1PIcHNCVkeHUh?=
EW-3 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVviTWVRUUN3ME2xNE43Ojh7IN88US=> MnLLV2FPT0WU
KY821 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Q[5FKSzVyPUGwMlc3OyEQvF2= M3zFPXNCVkeHUh?=
NCI-SNU-1 NYLzcVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL4dIQ2UUN3ME2xNU4xOjF5IN88US=> NUn2OldCW0GQR1XS
HCC2218 NXL6d3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37hfmlEPTB;MUGuN|k5PiEQvF2= M{TsW3NCVkeHUh?=
IM-9 NYjzdJpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvCTWM2OD1zMT61NVA3KM7:TR?= MmDDV2FPT0WU
NCI-H889 M13lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmSyTWM2OD1zMT61N|E{KM7:TR?= M4L3UXNCVkeHUh?=
HDLM-2 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjGdXA6UUN3ME2xNk41OTV7IN88US=> NU[2VXAxW0GQR1XS
LB2518-MEL MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3jTWM2OD1zMj62PFE2KM7:TR?= MWPTRW5ITVJ?
NCI-H23 NV;W[GM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonSTWM2OD1zMz6yOFI2KM7:TR?= NXjDZlNUW0GQR1XS
NB17 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nnRWlEPTB;MUOuOFU4QSEQvF2= M33NcnNCVkeHUh?=
NCI-H322M NYXoVlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF2LkSwOlgh|ryP NG\Cb2dUSU6JRWK=
SUP-T1 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDTeHZKSzVyPUG0MlQyOyEQvF2= NXr2SGJ{W0GQR1XS
ES3 M17nSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XzfWlEPTB;MUWuNFcxOyEQvF2= NGPTXIFUSU6JRWK=
ES5 NXmzcZNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULyXZNqUUN3ME2xOU4xPzh5IN88US=> M{PqS3NCVkeHUh?=
NCI-H1650 NV[1TGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu5TWM2OD1zNT60PVc6KM7:TR?= NH\6PZRUSU6JRWK=
NCI-H226 NELDN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXkNYJKSzVyPUG1Mlg4PjhizszN MVPTRW5ITVJ?
COR-L88 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF4LkOxOEDPxE1? M3P2THNCVkeHUh?=
SCC-15 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF4LkO4Olkh|ryP NXnsfo1CW0GQR1XS
GOTO NVK3d4lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDZPYNKSzVyPUG2MlQ4QTNizszN MlTlV2FPT0WU
SIMA M4S2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrkSmVzUUN3ME2xOk41QDB{IN88US=> NF3jN3lUSU6JRWK=
NCI-H1299 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDxTWM2OD1zNz6xOVkyKM7:TR?= MkS0V2FPT0WU
NCI-H1581 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF5LkSyNVkh|ryP NG\GXVFUSU6JRWK=
MHH-NB-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnvTWM2OD1zNz65Olg{KM7:TR?= NV;UZotoW0GQR1XS
MFM-223 NHnlWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3TcopKSzVyPUG4MlA2OzhizszN NXrpem8xW0GQR1XS
ES7 M1W5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7CTHBsUUN3ME2xPE42PDNzIN88US=> M1HuZXNCVkeHUh?=
JVM-3 NHzRRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzuXpQ4UUN3ME2xPE44OTdizszN NVn0R|JJW0GQR1XS
RL M1jTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rzUGlEPTB;MkCuN|g5KM7:TR?= NYqzSohGW0GQR1XS
EC-GI-10 NFnNPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf6TWM2OD1{MT6yNFQyKM7:TR?= MX\TRW5ITVJ?
LNCaP-Clone-FGC NHTsdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ETWM2OD1{MT62O|Y5KM7:TR?= M{nSNHNCVkeHUh?=
IMR-5 NGHB[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPmXW5KSzVyPUKxMlg1QTRizszN MV\TRW5ITVJ?
KP-N-YS NW[2fWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rlV2lEPTB;MkGuPFc2KM7:TR?= NVfB[XA3W0GQR1XS
Mo-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ{LkKxPFUh|ryP M3rxSHNCVkeHUh?=
NCI-H128 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\tPI1ZUUN3ME2yN{42QDV|IN88US=> MVvTRW5ITVJ?
RH-1 M33YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W5WmlEPTB;MkOuO|g3PiEQvF2= M33BcHNCVkeHUh?=
NCI-H2171 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ2LkK0PFUh|ryP NWjaWocyW0GQR1XS
RPMI-8866 M1HobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\6TWM2OD1{Nj63OFIh|ryP MULTRW5ITVJ?
SK-N-FI NH;PXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJ5LkO4NVEh|ryP NEDQXoJUSU6JRWK=
LOXIMVI MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJ5LkiwOVEh|ryP MXTTRW5ITVJ?
P31-FUJ M{fqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOxXmhqUUN3ME2zNU42Ozd2IN88US=> NH7DSY5USU6JRWK=
KMS-12-PE NEjxTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljPTWM2OD12OT61N|AzKM7:TR?= MlPjV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (59)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ